US4908389A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Penetration enhancement system
Assignee: Warner Lambert Co LLC
•
Filing: 1986-08-27
•
Granted: 1990-03-13
•
Expires: 2006-08-27
Abstract
Abstract The penetration of various drugs through living membranes, eg., skin, is improved by their use in topical compositions containing certain penetration-enhancer systems.
Inventors
- 👤 Majid Mahjour
- 👤 Uma Iyer
- 👤 Mahdi B. Fawzi
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-05 06:39
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0014; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K47/12; A61K47/14
Claims Analysis
Total Claims: 4
Claim 1
Independent Claim
108 words
A transmembranally administrable composition comprising: (a) about 0.2% to about 5% of a bioaffecting agent selected from the group consisting of procaterol, 4,5-dihydro-6-[4-(1H-imidazole-1-yl)phenyl]-5-methyl-3-(2H)-pyridazinone, morphine, hydromorphone, propanolol, chlorpheniramine and a pharmaceutically acceptable organic or inorganic acid, (b) about 1% to about 202% of a fatty component selected from the group consisting of linoleic acid, C 1 -C 3 linoleic esters, and a monohydroxy linoleyl alcohol, (c) about 80% to about 99% of a secondary component consisting of a mixture of a compound selected from the group consisting of isopropanol, propylene glycol, polyethylene glycol 400 and tetraglycol, and a compound selected from the group consisting of triacetin and triethyl citrate.
Claim 2
Dependent Claim
108 words
A transmembranally administrable composition comprising: (a) about 0.2% to about 5% of a bioaffecting agent selected from the group consisting of procaterol, 4,5-dihydro-6-[4-(1H-imidazole-1-yl)phenyl]-5-methyl-3-(2H)-pyridazinone, morphine, hydromorphone, propanolol, chlorpheniramine and a pharmaceutically acceptable organic or inorganic acid, (b) about 1% to about 202% of a fatty component selected from the group consisting of linoleic acid, C 1 -C 3 linoleic esters, and a monohydroxy linoleyl alcohol, (c) about 80% to about 99% of a secondary component consisting of a mixture of a compound selected from the group consisting of isopropanol, propylene glycol, polyethylene glycol 400 and tetraglycol, and a compound selected from the group consisting of triacetin and triethyl citrate.
Claim 3
Independent Claim
121 words
A method of administering a bioaffecting agent comprising contacting a transmembranally administrable composition comprising: (a) about 0.2% to about 5% of a bioaffecting agent selected from the group consisting of procaterol, 4,5-dihydro-6-[4-(1H-imidazole-1-yl)phenyl]-5-methyl-3-(2H)-pyridazinone, morphine, hydromorphone, propanolol, chlorpheniramine and a pharmaceutically acceptable organic or inorganic acid, (b) about 1% to about 20% of a fatty component selected from the group consisting of linoleic acid, C 1 -C 3 linoleic esters, and a monohydroxy linoleyl alcohol, (c) about 80% to about 99% of a secondary component consisting of a mixture of a compound selected from the group consisting of isopropanol, propylene glycol, polyethylene glycol 400 and tetraglycol, and a compound selected from the group consisting of triacetin and triethyl citrate with a living membrane.
Claim 4
Independent Claim
121 words
A method of administering a bioaffecting agent comprising contacting a transmembranally administrable composition comprising: (a) about 0.2% to about 5% of a bioaffecting agent selected from the group consisting of procaterol, 4,5-dihydro-6-[4-(1H-imidazole-1-yl)phenyl]-5-methyl-3-(2H)-pyridazinone, morphine, hydromorphone, propanolol, chlorpheniramine and a pharmaceutically acceptable organic or inorganic acid, (b) about 1% to about 20% of a fatty component selected from the group consisting of linoleic acid, C 1 -C 3 linoleic esters, and a monohydroxy linoleyl alcohol, (c) about 80% to about 99% of a secondary component consisting of a mixture of a compound selected from the group consisting of isopropanol, propylene glycol, polyethylene glycol 400 and tetraglycol, and a compound selected from the group consisting of triacetin and triethyl citrate with a living membrane.
References Cited (Backward Citations)
US4695465A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-03-12 | 1993-09-11 | 1994-03-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-03-12 | 1997-09-11 | 1998-03-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-03-12 | 2001-09-11 | 2002-03-13 | $7700.00 | Window Closed / Lapsed |